Protein therapeutics discovery with
next-generation AI
Helixon is developing technology platforms that transform the discovery of protein therapeutics.
Novel antibodies
Deep learning and
high-throughput biology
designing antibody sequences at massive scale, predicting their properties, validating via experiments, and self-improving iteratively.
We balance the tradeoff between exploration and exploitation and search the sequence landscape, aiming for more precise epitope targeting and better developability after each iterative design cycle.
Deep learning models of antibody-antigen interaction landscape
We train deep learning models to predict binding between antibodies and antigens. With ever-growing structural a=nd functional data, our models become more precise and detailed.
Design and synthesis of antibody library
Given an antigen, we efficiently search the antibody sequence space to identify molecules that target an epitope with significant therapeutic implications. A library of up to millions of antibodies are then synthesized for testing.
High-throughput profiling of antibody properties
Using a variety of technologies, we obtain functional and biophysical measurements of individual antibodies in our library in a high-throughput manner.
Iterations towards optimized antibodies
By repeating the previous steps, we learn from the successes and failures of earlier experiments, train better models, design a new library of candidates, and further improve antibodies with desired properties.
Deep learning optimized human antibody against SARS-Cov-2 variants
Protein structure can be predicted from its primary sequence with high accuracy
Working
Together
to out-evolve nature
We are building a team of passionate scientists and engineers to drive scientific advances and technology innovations for bringing better therapies and improving human health.